Quantum Genomics SA (ALQGC):企業の財務・戦略的SWOT分析

◆英語タイトル:Quantum Genomics SA (ALQGC) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14812
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥33,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Quantum Genomics SA (Quantum Genomics) is a biopharmaceutical company which develops novel medicines in the field of cardiovascular diseases. The company develops drugs to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition (BAPAI), a real triple action innovative therapeutic platform. Quantum Genomics BAPAI products pipeline include QGC001 for the treatment of high blood pressure with monotherapy drug; and QGC011 for the treatment of hypertension through combination therapy in pre-clinical phase. The company offers QGC006 for the optimization of the treatment of hypertension with a monotherapy drug; and QGC101 for the prevention and treatment of heart failure. The company partners with biotech research entities, academic teams, and pharmaceutical and bio-science companies to develop new drugs. QGS is headquartered in Paris, France.

Quantum Genomics SA Key Recent Developments

Feb 25,2019: Quantum Genomics Completes Enrollment in Its Pharmacokinetic Clinical Study of Firibastat
Feb 06,2019: Quantum Genomics Announces the Publication of Two Scientific Articles Confirming the Efficacy of Firibastat for Heart Failure
Apr 19,2018: Quantum Genomics enters a new phase of maturity with its BAPAIs Fast Growth strategic plan
Apr 09,2018: Quantum Genomics strengthens its governance
Mar 29,2018: Quantum Genomics publishes its financial results for the year 2017

This comprehensive SWOT profile of Quantum Genomics SA provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Quantum Genomics SA including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Quantum Genomics SA – Key Information
Quantum Genomics SA – Overview
Quantum Genomics SA – Key Employees
Quantum Genomics SA – Key Employee Biographies
Quantum Genomics SA – Key Operational Heads
Quantum Genomics SA – Major Products and Services
Quantum Genomics SA – History
Quantum Genomics SA – Company Statement
Quantum Genomics SA – Locations And Subsidiaries
Quantum Genomics SA – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Quantum Genomics SA – Business Description
Quantum Genomics SA – Corporate Strategy
Quantum Genomics SA – SWOT Analysis
SWOT Analysis – Overview
Quantum Genomics SA – Strengths
Quantum Genomics SA – Weaknesses
Quantum Genomics SA – Opportunities
Quantum Genomics SA – Threats
Quantum Genomics SA – Key Competitors

Section 3 – Company Financial Performance Charts

Quantum Genomics SA – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Quantum Genomics SA, Key Information
Quantum Genomics SA, Key Ratios
Quantum Genomics SA, Share Data
Quantum Genomics SA, Major Products and Services
Quantum Genomics SA, History
Quantum Genomics SA, Key Employees
Quantum Genomics SA, Key Employee Biographies
Quantum Genomics SA, Key Operational Heads
Quantum Genomics SA, Other Locations
Quantum Genomics SA, Subsidiaries
Quantum Genomics SA, Key Manufacturing facilities
Quantum Genomics SA, Key Competitors
Quantum Genomics SA, SWOT Analysis
Quantum Genomics SA, Ratios based on current share price
Quantum Genomics SA, Annual Ratios
Quantum Genomics SA, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Quantum Genomics SA, Performance Chart
Quantum Genomics SA, Ratio Charts

★海外企業調査レポート[Quantum Genomics SA (ALQGC):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nice-Pak Products, Inc.:企業の戦略・SWOT・財務情報
    Nice-Pak Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nice-Pak Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • PPL Corporation (PPL):石油・ガス:M&Aディール及び事業提携情報
    Summary PPL Corp (PPL) is an energy holding company. Through its subsidiaries, LG&E, Kentucky Utilities, and KU Energy, it generates, transmits, distributes, and sells electricity; and distributes and sells natural gas. The company produces electricity from coal, natural gas, oil, hydro, and solar s …
  • Tallgrass Energy Partners, LP (TEP)-石油・ガス分野:企業M&A・提携分析
    Summary Tallgrass Energy Partners, LP (Tallgrass Energy) is a midstream oil and gas company. It owns, operates, acquires and develops midstream energy assets in North America. The company offers natural gas transportation and storage services through its pipeline and natural gas processing assets to …
  • AcuFocus Inc:医療機器:M&Aディール及び事業提携情報
    Summary AcuFocus Inc (AcuFocus) is an ophthalmic medical device company that develops and markets technologies for the improvement of near vision. The company develops and markets breakthrough technologies for the improvement of vision. It’s IC-8 IOL, a small aperture lens that is designed for preby …
  • L’Occitane International SA:企業の戦略・SWOT・財務情報
    L'Occitane International SA - Strategy, SWOT and Corporate Finance Report Summary L'Occitane International SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析
    Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Belize Electricity Ltd:企業の戦略的SWOT分析
    Belize Electricity Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • French National Institute of Health and Medical Research:医療機器:M&Aディール及び事業提携情報
    Summary French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immu …
  • The Michaels Companies, Inc.:企業の戦略・SWOT・財務情報
    The Michaels Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Michaels Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Generex Biotechnology Corp (GNBT):医療機器:M&Aディール及び事業提携情報
    Summary Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulatio …
  • CEMEX, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    CEMEX, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary CEMEX, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Media-Saturn-Holding GmbH:戦略・SWOT・企業財務分析
    Media-Saturn-Holding GmbH - Strategy, SWOT and Corporate Finance Report Summary Media-Saturn-Holding GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sacgasco Ltd (SGC):石油・ガス:M&Aディール及び事業提携情報
    Summary Sacgasco Ltd (Sacgasco), formerly Australian Oil Company Ltd is an energy company that offers conventional oil and gas exploration, development and production across Australia. The company develops and produces clean natural gas in the Sacramento Basin, onshore California. It explores Sacram …
  • Ambrx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambrx Inc (Ambrx) is a biopharmaceutical company that offers discovery and development of protein-based medicines by using its expanded genetic code. The company provides pipeline product candidate’s portfolio such as ARX618 FGF21, PSMA ADC, CD70 ADC and Anti-CD3 X Folate. It develops pipeli …
  • Grundfos Holding AS:企業の戦略的SWOT分析
    Grundfos Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Greenpower Energy Ltd (GPP):石油・ガス:M&Aディール及び事業提携情報
    Summary Greenpower Energy Ltd (Greenpower) is an oil and gas, and mineral exploration and development company. The company’s business activities include acquisition, exploration, and development of petroleum, mineral and hydrothermal exploration properties. It explores for coal, lithium, tantalum, p …
  • Kancera AB (KAN):製薬・医療:M&Aディール及び事業提携情報
    Summary Kancera AB (Kancera) is a developer of drug candidates for the treatment of cancer. The company’s pipeline products include fractalkine inhibitor AZD8797, used to stop tumor growth; small molecule HDAC6 inhibitors, for neutralizing blood cancer; small molecule PFKFB3 inhibitors, for stopping …
  • AroCell AB (AROC):製薬・医療:M&Aディール及び事業提携情報
    Summary AroCell AB (AroCell), formerly Xi Bao Research AB, is a drug development company that develops and commercializes tests used for the prognosis and monitoring of treatment of cancer. The company develops TK 210 ELISA kits for measuring the enzyme TK1 which is a protein that is elevated in the …
  • Centre for Drug Design and Discovery-製薬・医療分野:企業M&A・提携分析
    Summary Centre for Drug Design and Discovery (CD3) is a biomedical research institution that discovers new small molecule drugs. The institution provides services such as silico molecule design, modelling and screening, medicinal chemistry, intellectual property rights support, business development, …
  • Hindustan ZInc Ltd:企業の戦略・SWOT・財務分析
    Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report Summary Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆